REGENXBIO's RGX-121 BLA Accepted by FDA Under Accelerated Approval Pathway
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy RGNX?
Source: Benzinga
- FDA Approval Update: The FDA has accepted REGENXBIO's RGX-121 BLA under the accelerated approval pathway; however, the PDUFA goal date has been extended from November 9, 2025, to February 8, 2026, indicating the agency's cautious approach to expedited approvals.
- Reasons for CRL: The FDA issued a Complete Response Letter (CRL) for RGX-121, citing concerns regarding study eligibility criteria and the appropriateness of a surrogate endpoint, suggesting that new studies and long-term follow-ups may be necessary, which poses challenges in an ultra-rare disease population.
- Market Reaction: Despite regulatory hurdles, REGENXBIO's stock shows strong momentum in the market, with analysts maintaining a
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.650
Low
19.00
Averages
29.71
High
45.00
Current: 8.650
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against REGENXBIO, alleging violations of federal securities laws from February 9, 2022, to January 27, 2026, indicating significant investor concern over the company's transparency and accountability.
- Allegations of Misrepresentation: The complaint claims that REGENXBIO made materially misleading statements regarding the development of RGX-111 gene therapy, particularly that optimistic projections about its clinical trial lacked a reasonable basis, potentially misleading investors about the company's future prospects.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by April 14, 2026, highlighting the legal team's commitment to safeguarding investor rights while emphasizing the potential impact of the class action on REGENXBIO's accountability.
- Contingency Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC will represent investors on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thereby reducing financial risk for investors and enhancing the appeal of participating in the lawsuit.
See More
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, confirmed his departure in April, prompting market interest, particularly as Moderna's stock rises due to his controversial drug review decisions.
- Positive Market Reaction: Analyst from William Blair noted that investors are optimistic about Prasad's exit, believing it will benefit regulatory approvals for rare disease drugs, especially those utilizing single-arm studies and external controls.
- Potential Gains for Moderna: With Prasad's departure, Moderna's mRNA-1010 vaccine could qualify for full approval in adults aged 65 and older, potentially sparing the company from conducting an additional costly vaccine efficacy study.
- Stock Price Increases: Following the news of Prasad's resignation, stocks of Solid Biosciences and Capricor Therapeutics rose by 12.15% and 9.07%, respectively, indicating increased market confidence in rare disease treatments.
See More
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has advised REGENXBIO investors of a class action for those who purchased securities between February 9, 2022, and January 27, 2026, with a deadline of April 14, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant, causing the company's stock price to plummet nearly 18%, raising serious concerns about the safety and efficacy of its clinical trials.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy via phone or email to discuss options for recovering losses, highlighting the firm's commitment to investor rights.
- Company Background: REGENXBIO is a clinical-stage biotechnology firm focused on gene therapies, developing RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (Hurler syndrome), with its market prospects now jeopardized by the ongoing litigation.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Biotech Stocks Surge Following FDA Vaccine Chief's Departure
- Stock Price Surge: Following the announcement of FDA vaccine chief Vinay Prasad's departure, shares of UniQure (QURE) rose approximately 35%, Capricor Therapeutics (CAPR) increased by 11%, Regenxbio (RGNX) climbed 14.5%, Replimune (REPL) gained 9.8%, and Solid Biosciences (SLDB) saw a 6% rise, reflecting optimistic market sentiment towards the biotech sector.
- Positive Industry Reaction: Analyst Paul Matteis noted that Prasad's exit is a “big win for biotech,” particularly for rare disease research, potentially paving the way for UniQure to make progress with its AMT-130 Huntington's disease gene therapy candidate after limited advancements in their recent FDA meeting.
- Improved Regulatory Outlook: Truist's Danielle Brill views Prasad's departure as providing greater predictability in the regulatory process for industry stakeholders, although the overall outlook remains unclear, which may attract more investor interest in the biotech field.
- Impact of Leadership Volatility: RBC Capital Markets' Brian Abrahams highlighted that while Prasad's exit may be perceived positively, the ongoing volatility in regulatory leadership continues to leave many investors on the sidelines, affecting the developmental direction of biotech companies.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Out-of-Pocket Fees: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring that investors can pursue potential compensation without additional financial burden.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, highlighting misconduct during clinical trials.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
See More
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against REGENXBIO, alleging violations of federal securities laws from February 9, 2022, to January 27, 2026, indicating significant investor concern over the company's transparency and accountability.
- Allegations of Misrepresentation: The complaint claims that REGENXBIO made materially misleading statements regarding the development of RGX-111 gene therapy, particularly that optimistic projections about its clinical trial lacked a reasonable basis, potentially misleading investors about the company's future prospects.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by April 14, 2026, highlighting the legal team's commitment to safeguarding investor rights while emphasizing the potential impact of the class action on REGENXBIO's accountability.
- Contingency Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC will represent investors on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thereby reducing financial risk for investors and enhancing the appeal of participating in the lawsuit.
See More
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
- Leadership Change: Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, confirmed his departure in April, prompting market interest, particularly as Moderna's stock rises due to his controversial drug review decisions.
- Positive Market Reaction: Analyst from William Blair noted that investors are optimistic about Prasad's exit, believing it will benefit regulatory approvals for rare disease drugs, especially those utilizing single-arm studies and external controls.
- Potential Gains for Moderna: With Prasad's departure, Moderna's mRNA-1010 vaccine could qualify for full approval in adults aged 65 and older, potentially sparing the company from conducting an additional costly vaccine efficacy study.
- Stock Price Increases: Following the news of Prasad's resignation, stocks of Solid Biosciences and Capricor Therapeutics rose by 12.15% and 9.07%, respectively, indicating increased market confidence in rare disease treatments.
See More
REGENXBIO Investors Class Action Notice Issued
- Class Action Initiated: The Portnoy Law Firm has advised REGENXBIO investors of a class action for those who purchased securities between February 9, 2022, and January 27, 2026, with a deadline of April 14, 2026, for filing a lead plaintiff motion to protect their legal rights.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 gene therapy due to the discovery of an intraventricular CNS tumor in a trial participant, causing the company's stock price to plummet nearly 18%, raising serious concerns about the safety and efficacy of its clinical trials.
- Legal Consultation Services: The Portnoy Law Firm offers complimentary case evaluations and encourages investors to contact attorney Lesley F. Portnoy via phone or email to discuss options for recovering losses, highlighting the firm's commitment to investor rights.
- Company Background: REGENXBIO is a clinical-stage biotechnology firm focused on gene therapies, developing RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (Hurler syndrome), with its market prospects now jeopardized by the ongoing litigation.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
Biotech Stocks Surge Following FDA Vaccine Chief's Departure
- Stock Price Surge: Following the announcement of FDA vaccine chief Vinay Prasad's departure, shares of UniQure (QURE) rose approximately 35%, Capricor Therapeutics (CAPR) increased by 11%, Regenxbio (RGNX) climbed 14.5%, Replimune (REPL) gained 9.8%, and Solid Biosciences (SLDB) saw a 6% rise, reflecting optimistic market sentiment towards the biotech sector.
- Positive Industry Reaction: Analyst Paul Matteis noted that Prasad's exit is a “big win for biotech,” particularly for rare disease research, potentially paving the way for UniQure to make progress with its AMT-130 Huntington's disease gene therapy candidate after limited advancements in their recent FDA meeting.
- Improved Regulatory Outlook: Truist's Danielle Brill views Prasad's departure as providing greater predictability in the regulatory process for industry stakeholders, although the overall outlook remains unclear, which may attract more investor interest in the biotech field.
- Impact of Leadership Volatility: RBC Capital Markets' Brian Abrahams highlighted that while Prasad's exit may be perceived positively, the ongoing volatility in regulatory leadership continues to leave many investors on the sidelines, affecting the developmental direction of biotech companies.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Out-of-Pocket Fees: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, ensuring that investors can pursue potential compensation without additional financial burden.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, highlighting misconduct during clinical trials.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
See More
